Cspc Innovation Pharmaceutical Co.,Ltd.(300765),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

300765 Cspc Innovation Pharmaceutical Co.,Ltd.

Wait For Opening 08-20 09:30:00

49.96

+6.81

+15.78%

High49.96	Low49.96	Vol1.47M
Open49.96	D1 Closing43.15	Amplitude0.00%
Mkt Cap70.19B	Tradable Cap70.19B	Total Shares1.41B
T/O73.28M	T/O Rate0.10%	Tradable Shares1.41B
P/B15.4	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"300765","market":"SZ","secType":"STK","nameCN":"Cspc Innovation Pharmaceutical Co.,Ltd.","latestPrice":49.96,"timestamp":1787189193000,"preClose":43.15,"halted":0,"volume":1466800,"delay":0,"changeRate":0.1578,"floatShares":1405000000,"shares":1405000000,"eps":0.7282,"marketStatus":"Wait For Opening","change":6.81,"latestTime":"08-20 09:30:00","open":49.96,"high":49.96,"low":49.96,"amount":73281300,"amplitude":0,"askPrice":49.96,"askSize":195,"bidPrice":49.62,"bidSize":270,"shortable":0,"etf":0,"ttmEps":0.7282,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1787189400000},"marketStatusCode":7,"adr":0,"adjPreClose":43.15,"symbolType":"stock","openAndCloseTimeList":[[1787189400000,1787196600000],[1787202000000,1787209200000]],"highLimit":47.47,"lowLimit":38.84,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":1404592944,"isCdr":false,"pbRate":15.4,"roa":"--","peRate":68.607525,"roe":"38.2%","epsLYR":-0.1731,"committee":-0.837096,"marketValue":70173000000,"turnoverRate":0.001,"status":0,"floatMarketCap":70173000000},"requestUrl":"/m/hq/s/300765/tweets","defaultTab":"tweets","newsList":[{"id":"1169059614","title":"CSPC Innovation Subsidiary Initiates Phase Ib/II Clinical Trial for SYS6090","url":"https://stock-news.laohu8.com/highlight/detail?id=1169059614","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169059614?lang=en_us&edition=fundamental","pubTime":"2026-08-19 16:04","pubTimestamp":1787126666,"startTime":"0","endTime":"0","summary":"Cspc Innovation Pharmaceutical Co., Ltd. (300765.SZ) has announced that its controlling subsidiary, CSPC Megalith Biopharmaceutical Co., Ltd., recently kicked off a Phase Ib/II clinical trial...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDTX","PSYK","BK0226","IBBJ","BMED","300765","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660487988","title":"CSPC Innovation Posts RMB 1.26 Billion H1 Net Profit on RMB 3.24 Billion Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2660487988","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660487988?lang=en_us&edition=fundamental","pubTime":"2026-08-17 20:19","pubTimestamp":1786969143,"startTime":"0","endTime":"0","summary":"CSPC Innovation posts RMB 1.26 billion H1 net profit on RMB 3.24 billion revenueCSPC’s subsidiary CSPC Innovation reported 1H 2026 revenue of RMB 3.24 billion, up 208.72% year on year.Net profit attri","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nNDL28Hkdn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0052756011.USD","LU0784383803.USD","LU2237443895.HKD","IE00B5MMRT66.SGD","LU0661504455.SGD","LU1003077747.HKD","BK1515","LU0203347892.USD","LU1863844665.USD","LU1104425308.USD","LU1261432733.SGD","LU2112291526.USD","LU1267930490.SGD","KURE","LU0047473722.SGD","LU0390134368.USD","LU1226288253.USD","LU1807302812.USD","LU0266013472.USD","SGXZ57979304.SGD","AZN.UK","LU0315179316.USD","LU2237443622.USD","LU0140636845.USD","LU1951186391.HKD","IE00B543WZ88.USD","HK0000165453.HKD","LU1196032939.SGD","LU1046234339.USD","LU1960683339.HKD","300765","LU1023059063.AUD","LU0882574055.USD","LU1061106388.HKD","LU1226288170.HKD","LU2091194634.USD","01093","03165","LU0964806797.USD","LU3187612489.SGD","LU0211326839.USD","LU1983299246.USD","BK1521","LU0784385840.USD","LU2114397693.USD","LU2324357040.USD","LU0738911758.USD","LU1267930813.SGD","LU0128525689.USD","LU0920840948.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1156632772","title":"Cspc Innovation Pharmaceutical Reports Net Profit of 1.261 Billion Yuan in First Half After Turning Losses Around","url":"https://stock-news.laohu8.com/highlight/detail?id=1156632772","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156632772?lang=en_us&edition=fundamental","pubTime":"2026-08-17 16:51","pubTimestamp":1786956680,"startTime":"0","endTime":"0","summary":"Cspc Innovation Pharmaceutical Co., Ltd. (300765.SZ) has released its semi-annual report for the first half of 2026, showing a significant turnaround. The company achieved operating revenue of 3.24...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660553485","title":"CSPC Innovation Pharmaceutical H1 Net Profit 1.3 Billion Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=2660553485","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660553485?lang=en_us&edition=fundamental","pubTime":"2026-08-17 16:49","pubTimestamp":1786956561,"startTime":"0","endTime":"0","summary":"Aug 17 (Reuters) - CSPC Innovation Pharmaceutical Co., Ltd. <300765.SZ>::*H1 NET PROFIT 1.3 BILLION YUAN ($192.94 million)((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))Source Date/Time = 17-AUG-202608:33:31 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nRSD7jdYvX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2039709279.SGD","LU1008478684.HKD","BK1521","LU0072913022.USD","LU1226288170.HKD","LU1993786604.SGD","LU0501845795.SGD","01093","LU0067412154.USD","LU1152091168.USD","LU1226287792.SGD","LU0326950275.SGD","LU1807302812.USD","LU0315179316.USD","LU0880133367.SGD","300765","LU1813983027.USD","IE00B5MMRT66.SGD","IE0008369823.USD","BK1515","IE0008368742.USD","LU1226287529.USD","LU1951186391.HKD","LU1226288253.USD","LU0314109678.HKD","IE00BZ08YT58.USD","LU0140636845.USD","LU1328277881.USD","IE00B031HY20.USD","LU1226287875.USD","SG9999004220.SGD","IE00B543WZ88.USD","BK0226","IE00BZ08YS42.EUR","IE00BZ08YR35.GBP","LU1152091754.HKD","LU1960683339.HKD","KURE","HK0000165453.HKD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660483136","title":"CSPC Innovation Pharmaceutical H1 Net Profit 1.3 Bln Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=2660483136","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2660483136?lang=en_us&edition=fundamental","pubTime":"2026-08-17 16:33","pubTimestamp":1786955611,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260817:nL4N44E0GL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659618035","title":"CSPC Innovation Pharmaceutical Gets $30 Million Initial Payment for Nucleic Acid Development Deal With AstraZeneca","url":"https://stock-news.laohu8.com/highlight/detail?id=2659618035","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659618035?lang=en_us&edition=fundamental","pubTime":"2026-08-13 11:43","pubTimestamp":1786592598,"startTime":"0","endTime":"0","summary":"CSPC Innovation Pharmaceutical , through unit Jushi Biosciences, received the initial payment of $30 million from AstraZeneca for the development of the small nucleic acid pipeline, according to a Wednesday disclosure on the Shenzhen bourse.The Chinese pharmaceutical company's shares rose 2% during Thursday's morning trade.Jushi Biosciences signed a deal with AstraZeneca in July to develop nucleic acids for drug production.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101412793","title":"Cspc Innovation's Subsidiary Receives $30 Million Upfront Payment from AstraZeneca","url":"https://stock-news.laohu8.com/highlight/detail?id=1101412793","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101412793?lang=en_us&edition=fundamental","pubTime":"2026-08-12 18:56","pubTimestamp":1786532201,"startTime":"0","endTime":"0","summary":"Cspc Innovation Pharmaceutical Co., Ltd. (300765.SZ) announced that on July 1, 2026, its controlling subsidiary, Jushi Biologics, signed a Collaboration, Option, and License Agreement with...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZNH","LU1267930573.SGD","LU2456880835.USD","LU0708994859.HKD","IE00B3T34201.USD","BK0226","LU2237443549.SGD","BK4588","LU2237443895.HKD","LU2237443622.USD","AZN","300765","LU0058720904.USD","LU2237443978.SGD","LU0310800379.SGD","BK4568","LU0289739699.SGD","LU2237443382.USD","LU2237443465.HKD","LU2468319806.SGD","LU1829250122.USD","BK4007","LU0029864427.USD","LU2417539215.USD","LU0889565916.HKD","LU2236285917.USD","LU0109394709.USD","LU0320765992.SGD","LU0432979614.USD","LU0128525929.USD","LU2089984988.USD","BK4585","LU2462157665.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658964487","title":"CSPC Innovation Pharmaceutical Unit Receives FDA Clearance for Monkeypox Vaccine Trial; Shares Up 6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658964487","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2658964487?lang=en_us&edition=fundamental","pubTime":"2026-08-11 13:42","pubTimestamp":1786426962,"startTime":"0","endTime":"0","summary":"CSPC Innovation Pharmaceutical  subsidiary CSPC Jushi Biopharmaceutical received U.S. Food and Drug Administration clearance to conduct clinical trials of its SYS6037 monkeypox vaccine candidate.The investigational new drug application for the vaccine passed safety review by the U.S. FDA, according to an after-hours filing on Monday with the Shenzhen bourse.Shares jumped nearly 6% during afternoon trading on Tuesday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","300765","BK4585","BK0226","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186200098","title":"Cspc Innovation Subsidiary Gets FDA Clearance for Monkeypox mRNA Vaccine Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=1186200098","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186200098?lang=en_us&edition=fundamental","pubTime":"2026-08-10 15:52","pubTimestamp":1786348339,"startTime":"0","endTime":"0","summary":"Cspc Innovation Pharmaceutical Co.,Ltd. (300765.SZ) announced that its controlling subsidiary, CSPC Megalith Biopharmaceutical Co., Ltd., received notification from the U.S. Food and Drug...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["300765","PSYK","MDTX","IBBQ","BMED","MRNX","BK0226","IBBJ","MRNY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656584815","title":"CSPC Innovation Pharmaceutical Launches Phase Ib/II Trial for Colorectal Cancer Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2656584815","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656584815?lang=en_us&edition=fundamental","pubTime":"2026-08-04 12:31","pubTimestamp":1785817914,"startTime":"0","endTime":"0","summary":"CSPC Innovation Pharmaceutical  subsidiary MegaStone started a Phase Ib/II clinical trial for SYS6090 injection in patients with advanced or metastatic colorectal cancer.The open-label, multi-center trial will evaluate the safety, tolerability and efficacy of the combination regimen, according to a Monday aftermarket filing on the Shenzhen bourse.Patient recruitment is underway.Shares of the company rose 2% in recent trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1196848313","title":"Cspc Innovation Pharmaceutical Initiates Phase Ib/II Trial for SYS6090 Combination Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1196848313","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196848313?lang=en_us&edition=fundamental","pubTime":"2026-08-03 16:38","pubTimestamp":1785746310,"startTime":"0","endTime":"0","summary":"The company Cspc Innovation Pharmaceutical Co.,Ltd. (300765.SZ) has announced that its controlled subsidiary, CSPC Megalith Biopharmaceutical Co., Ltd., has recently launched a Phase Ib/II clinical...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0226","MDTX","IBBJ","PSYK","BMED","300765","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105692020","title":"Cspc Innovation Pharmaceutical's Subsidiary Launches Phase II Trial for SYS6041","url":"https://stock-news.laohu8.com/highlight/detail?id=1105692020","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105692020?lang=en_us&edition=fundamental","pubTime":"2026-07-31 16:32","pubTimestamp":1785486734,"startTime":"0","endTime":"0","summary":"Cspc Innovation Pharmaceutical Co., Ltd (300765.SZ) has announced that its controlling subsidiary, CSPC Megalith Biopharmaceutical Co., Ltd., has initiated an open-label, multi-cohort, multicenter...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["300765","IBBQ","BK0226","BMED","PSYK","MDTX","IBBJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655382800","title":"CSPC Innovation Pharma Subsidiary Gets FDA Clinical Trial Approval for CRB-701 Cancer Drug; Shares Slide 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655382800","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655382800?lang=en_us&edition=fundamental","pubTime":"2026-07-30 14:25","pubTimestamp":1785392707,"startTime":"0","endTime":"0","summary":"CSPC Innovation Pharmaceutical  subsidiary CSPC Jushi Biopharmaceutical received U.S. Food and Drug Administration clinical trial approval for its CRB-701 drug, according to a Wednesday after-hours filing with the Shenzhen Stock Exchange.The drug received approval for its TEMPO-1 randomized controlled clinical trial for the drug targeting Nectin-4, an antigen expressed in urothelial carcinoma as well as in cervical cancer and head and neck squamous cell carcinoma.Shares fell 4% during afternoon trading on Thursday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0226","BK4588","300765","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130968351","title":"Cspc Innovation Subsidiary's Licensed Drug CRB-701 (SYS6002) Gets FDA Nod for Phase 3 Trial in Second-Line Oropharyngeal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=1130968351","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1130968351?lang=en_us&edition=fundamental","pubTime":"2026-07-29 18:00","pubTimestamp":1785319244,"startTime":"0","endTime":"0","summary":"Cspc Innovation Pharmaceutical Co., Ltd. (300765.SZ) announced that it has received notification from Corbus Pharmaceuticals, Inc. regarding a key regulatory milestone.The company’s controlling...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMED","IBBJ","IBBQ","PSYK","MDTX","LABU","BK4588","BK4585","300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107941055","title":"Cspc Innovation Pharmaceutical forecasts net profit of 1.18 to 1.36 billion yuan for first half of 2026, reversing year-on-year loss","url":"https://stock-news.laohu8.com/highlight/detail?id=1107941055","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107941055?lang=en_us&edition=fundamental","pubTime":"2026-07-27 17:38","pubTimestamp":1785145095,"startTime":"0","endTime":"0","summary":"Cspc Innovation Pharmaceutical Co., Ltd. (300765.SZ) has released its performance forecast for the first half of 2026, projecting a net profit attributable to shareholders of the listed company...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654016865","title":"CSPC Innovation Pharma, CSPC Pharmaceutical Group Unit, Forecasts H1 Net Profit at 1.18 Billion-1.36 Billion Yuan","url":"https://stock-news.laohu8.com/highlight/detail?id=2654016865","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654016865?lang=en_us&edition=fundamental","pubTime":"2026-07-27 17:34","pubTimestamp":1785144884,"startTime":"0","endTime":"0","summary":"CSPC Innovation Pharma, CSPC Pharmaceutical Group unit, forecasts H1 net profit at 1.18 billion-1.36 billion yuanCSPC Innovation Pharmaceutical, a subsidiary of CSPC Pharmaceutical Group, guided for H","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nNDL9WrKMv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2089284900.SGD","LU2293690249.USD","BK5011","IE00BZ08YT58.USD","BK1191","LU0963555726.SGD","LU1989772840.SGD","LU0976567544.SGD","01093","LU0545039389.USD","LU1153585028.USD","KURE","LU1051770623.HKD","IE00BJJMRZ35.SGD","LU2293690082.USD","LU2324357040.USD","LU2279689827.SGD","LU0203347892.USD","LU0949170772.SGD","LU0997586515.USD","300765","LU0964806797.USD","LU0211326755.USD","LU0315179316.USD","LU1481599808.USD","03165","LU1923622614.USD","LU1152091754.HKD","LU1078025761.USD","LU0052756011.USD","LU1328277881.USD","LU0920840948.USD","IE0008369823.USD","LU0972486137.USD","LU0390134368.USD","LU2237443978.SGD","LU0140636845.USD","AZN.UK","LU0203345920.USD","IE0008368742.USD","LU1487256676.USD","LU2237443895.HKD","LU0072913022.USD","IE00B4R5TH58.HKD","LU2091194634.USD","LU0122379950.USD","LU0969580561.USD","LU1814569148.SGD","LU1989772923.USD","LU1481600234.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652470300","title":"CSPC Innovation Pharmaceutical Receives China Approval for SYS6043 Clinical Trial; Shares Slide 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2652470300","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652470300?lang=en_us&edition=fundamental","pubTime":"2026-07-17 14:33","pubTimestamp":1784269999,"startTime":"0","endTime":"0","summary":"CSPC Innovation Pharmaceutical  subsidiary Jushi Biopharmaceutical received approval from China's National Medical Products Administration for the phase 3 trial of its self-developed SYS6043 drug, according to a Thursday after-hours filing with the Shanghai Stock Exchange.SYS6043 is an antibody-drug conjugate that targets B7-H3 and releases a small molecule toxin to kill tumor cells, the company said in its filing.The trial will evaluate the response in patients with platinum-resistant advanced ovarian cancer, primary peritoneal cancer, and fallopian tube cancer.Shares in the drug company fell 4% during afternoon trading on Friday.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134407705","title":"CSPC Innovation Pharmaceutical's Subsidiary Initiates Phase III Trial for SYS6043","url":"https://stock-news.laohu8.com/highlight/detail?id=1134407705","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134407705?lang=en_us&edition=fundamental","pubTime":"2026-07-16 17:06","pubTimestamp":1784192793,"startTime":"0","endTime":"0","summary":"An announcement has been made by CSPC Innovation Pharmaceutical Co.,Ltd. (ASX: 300765) regarding its majority-owned subsidiary, CSPC Group Jushi Bio-pharmaceutical Co., Ltd. (Jushi Bio). The...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0226","300765","BMED","IBBQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115861661","title":"Resolutions Passed at CSPC Innovation Pharmaceutical's Third Extraordinary Shareholders' Meeting of 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1115861661","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115861661?lang=en_us&edition=fundamental","pubTime":"2026-07-08 22:21","pubTimestamp":1783520505,"startTime":"0","endTime":"0","summary":"Cspc Innovation Pharmaceutical Co.,Ltd. (ASX: 300765) has announced that the resolutions from its third extraordinary shareholders' meeting of the year 2026 have been passed.The meeting, held on July...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["300765","BK0226"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155535171","title":"CSPC Innovation Pharmaceutical's Investigational Drug SYS6043 Granted Breakthrough Therapy Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=1155535171","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155535171?lang=en_us&edition=fundamental","pubTime":"2026-07-02 17:05","pubTimestamp":1782983106,"startTime":"0","endTime":"0","summary":"The investigational drug SYS6043 for injection, developed by CSPC Innovation Pharmaceutical Co.,Ltd.'s (300765.SZ) controlling subsidiary CSPC Jushi Biotechnology Co., Ltd., has been included in the...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0226","300765"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787189250197,"stockEarnings":[{"period":"1week","weight":0.0094},{"period":"1month","weight":0.0368},{"period":"3month","weight":0.5024},{"period":"6month","weight":0.285},{"period":"1year","weight":-0.1172},{"period":"ytd","weight":0.1963}],"compareEarnings":[{"period":"1week","weight":-0.0132},{"period":"1month","weight":0.0259},{"period":"3month","weight":-0.0448},{"period":"6month","weight":-0.046},{"period":"1year","weight":0.0448},{"period":"ytd","weight":-0.0188}],"compareStock":{"symbol":"000001.SH","name":"SSE Comp"},"companyName":"石药创新制药股份有限公司","boardCode":"AI0014","boardName":"食品制造业","stockholders":"31534人(较上一季度增加31.88%)","perCapita":"44542股","listingDate":"2019-03-22","address":"河北省石家庄市栾城区张举路62号","registeredCapital":"140459万元","survey":"　　石药创新制药股份有限公司的主营业务是生物制药、功能性原料及保健食品的研发、生产与商业化。公司的主要产品是抗体药物、ADC药物、mRNA疫苗、药品、咖啡因、阿卡波糖、无水葡萄糖原料及果维康维生素C含片、维生素B族含片。公司是国内首批实现mRNA疫苗产业化、ADC与抗体药物管线布局最完整的创新型生物药企业之一，已发展成为集源头创新、临床转化、规模生产与国际商业化于一体的高新技术企业。","listedPrice":24.47},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Cspc Innovation Pharmaceutical Co.,Ltd.(300765),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Cspc Innovation Pharmaceutical Co.,Ltd.(300765) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Cspc Innovation Pharmaceutical Co.,Ltd.,300765,Cspc Innovation Pharmaceutical Co.,Ltd.股票,Cspc Innovation Pharmaceutical Co.,Ltd.股票老虎,Cspc Innovation Pharmaceutical Co.,Ltd.股票老虎国际,Cspc Innovation Pharmaceutical Co.,Ltd.行情,Cspc Innovation Pharmaceutical Co.,Ltd.股票行情,Cspc Innovation Pharmaceutical Co.,Ltd.股价,Cspc Innovation Pharmaceutical Co.,Ltd.股市,Cspc Innovation Pharmaceutical Co.,Ltd.股票价格,Cspc Innovation Pharmaceutical Co.,Ltd.股票交易,Cspc Innovation Pharmaceutical Co.,Ltd.股票购买,Cspc Innovation Pharmaceutical Co.,Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Cspc Innovation Pharmaceutical Co.,Ltd.(300765),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Cspc Innovation Pharmaceutical Co.,Ltd.(300765) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction